^
BIOMARKER:

MET amplification

i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
MET amplification
Non Small Cell Lung Cancer
REGN5093
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
MET amplification
Non Small Cell Lung Cancer
crizotinib
Sensitive
:
A2
MET amplification
Non Small Cell Lung Cancer
tepotinib
Sensitive
:
A2
MET amplification
Renal Cell Carcinoma
savolitinib
Sensitive
:
A2
MET amplification
Gastroesophageal Junction Adenocarcinoma
AMG 102
Resistant
:
B
MET amplification
Gastric Adenocarcinoma
AMG 102
Resistant
:
B
MET amplification
Non Small Cell Lung Cancer
bevacizumab + crizotinib
Sensitive
:
C2
MET amplification
Non Small Cell Lung Cancer
SCC244
Sensitive
:
C2
MET amplification
Non Small Cell Lung Cancer
gefitinib + CT053PTSA
Sensitive
:
C2
MET amplification
Gastric Cancer
TPX-0022
Sensitive
:
C2
MET amplification
Non Small Cell Lung Cancer
osimertinib + savolitinib
Sensitive
:
C2
MET amplification
Lung Cancer
tepotinib
Sensitive
:
C2
MET amplification
Non Small Cell Lung Cancer
APL-101
Sensitive
:
C2
MET amplification
Non Small Cell Lung Cancer
capmatinib
Sensitive
:
C2
MET amplification
Gastric Cancer
savolitinib
Sensitive
:
C2
MET amplification
Renal Cell Carcinoma
crizotinib
Sensitive
:
C2
MET amplification
Head and Neck Cancer
crizotinib
Sensitive
:
C2
MET amplification
Gastric Cancer
tepotinib
Sensitive
:
C2
MET amplification
Gastric Adenocarcinoma
crizotinib
Sensitive
:
C3
MET amplification
Non Small Cell Lung Cancer
U3-1402
Sensitive
:
C3
MET amplification
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
MET amplification
Gallbladder Cancer
crizotinib
Sensitive
:
C3
MET amplification
Non Small Cell Lung Cancer
c-MET inhibitor
Sensitive
:
C3
MET amplification
Colorectal Cancer
TPX-0022
Sensitive
:
C3
MET amplification
Non Small Cell Lung Cancer
gefitinib + savolitinib
Sensitive
:
C3
MET amplification
Non Small Cell Lung Cancer
erlotinib
Resistant
:
C3
MET amplification
Solid Tumor
TQ-B3101
Sensitive
:
C3
MET amplification
Gastric Cancer
crizotinib
Sensitive
:
C3
MET amplification
Lung Adenocarcinoma
crizotinib + osimertinib
Sensitive
:
C3
MET amplification
Non Small Cell Lung Cancer
gefitinib
Resistant
:
C3
MET amplification
Gastroesophageal Cancer
crizotinib
Sensitive
:
C3
MET amplification
Lung Adenocarcinoma
crizotinib
Sensitive
:
C3
MET amplification
Colorectal Cancer
cetuximab
Resistant
:
C3